| Literature DB >> 31915636 |
Sin Geun Kim1, Hyung Joo Suh2, Sung Hee Han3, Hyun-Sun Lee4, Hyo-Won Kim5, Hoon Kim6.
Abstract
Encapsulated curcumin (ENCC) was prepared from a commercial curcuminoids complex and was evaluated for its intestinal permeability and hepatoprotective effects. Intestinal permeability was evaluated using a Caco-2 intestinal cell monolayer system and the non-everted gut sac method. The hepatoprotective effect was evaluated in experimental rats administered alcohol for 4 weeks. The intestinal permeability results suggested that encapsulation is a useful method for enhancing adsorption of curcumin via the intestinal epithelium. ENCC administration resulted in the significant reduction of various serum indicators. Notably, most of the indicators elevated by ethanol decreased below normal levels when rats were administered a high dose of ENCC. Oral administration of ENCC also augmented the activity of glutathione peroxidase in the liver, and both normal curcumin and ENCC significantly alleviated high levels of malondialdehyde. Our results demonstrate a significant hepatoprotective effect of ENCC in vivo owing to its ability to improve bioavailability of curcumin.Entities:
Keywords: bioavailability; curcumin; encapsulation; hepatoprotective effect; intestinal permeability
Year: 2019 PMID: 31915636 PMCID: PMC6941725 DOI: 10.3746/pnf.2019.24.4.410
Source DB: PubMed Journal: Prev Nutr Food Sci ISSN: 2287-1098
Experimental design for the oral administration of normal and encapsulated curcumins in a rat model of chronic hepatic disease induced by ethanol
| Group | Induction of alcoholic cirrhosis | Sample treatment |
|---|---|---|
| NOR | Saline with 1% Tween 20 | – |
| CON | 0.8 g of 30% EtOH with 1% Tween 20 | – |
| NCC-L | 0.8 g of 30% EtOH with 1% Tween 20 | 100 mg/kg of NCC |
| NCC-H | 0.8 g of 30% EtOH with 1% Tween 20 | 300 mg/kg of NCC |
| ENCC-L | 0.8 g of 30% EtOH with 1% Tween 20 | 100 mg/kg of ENCC |
| ENCC-H | 0.8 g of 30% EtOH with 1% Tween 20 | 300 mg/kg of ENCC |
NOR, normal control; CON, alcoholic cirrhosis control; NCC, normal curcumin; ENCC, encapsulated curcumin.
Fig. 1In vitro permeability of normal and encapsulated curcumins in Caco-2 intestinal epithelial cells over time. Caco-2 cells were grown in transwell insert plates to form an intestinal monolayer. At 30, 60, and 90 min following treatment of the cell monolayer, the level of curcumin was determined both (A) inside cells (curcumin not absorbed through the monolayer) and (B) outside of the cells (curcumin through the monolayer).
Fig. 2Comparison of absorption rate between normal and encapsulated curcumins using the non-everted intestinal sac method. A 10-cm intestinal sac was randomly prepared from SD rats, and normal and encapsulated curcumins were injected inside of the sac. At 30, 60, and 90 min following sample injection inside the sac, the level of curcumin was determined both inside (curcumin not-absorbed through the intestinal sac) and outside of the sac (curcumin absorbed through the intestinal sac). (A) Change of absorbance measured at 422 nm outside of the sac over time. (B) Curcumin concentration calculated from absorbance. (C) Change of curcumin concentration inside of the sac over time.
Effects of the oral administration of normal and encapsulated curcumins in a rat model of chronic hepatic disease induced by ethanol
| Group | Heart | Liver | Spleen | Kidney |
|---|---|---|---|---|
| NOR | 0.37±0.01b | 4.30±0.05 | 0.21±0.02a | 0.80±0.04 |
| CON | 0.44±0.01a | 4.13±0.10 | 0.19±0.01ab | 0.76±0.01 |
| NCC-L | 0.39±0.01b | 4.25±0.06 | 0.18±0.00b | 0.79±0.01 |
| NCC-H | 0.39±0.00b | 4.19±0.09 | 0.18±0.01ab | 0.78±0.03 |
| ENCC-L | 0.39±0.01b | 4.15±0.10 | 0.18±0.01ab | 0.81±0.00 |
| ENCC-H | 0.39±0.01b | 4.38±0.08 | 0.19±0.00ab | 0.79±0.02 |
Group names refer to those described in Table 1.
Different letters (a,b) in a column indicate a statistically significant difference among groups (P <0.05).
Not significant.
Biochemistry analysis in serum isolated from liver disease-induced experimental rats
| Group | ALT (U/L) | AST (U/L) | LDH (U/L) | TCHO (mg/dL) | TG (mg/dL) |
|---|---|---|---|---|---|
| NOR | 30.25±0.48cd | 44.50±0.65d | 212.25±6.92b | 86.75±6.80c | 118.00±6.22d |
| CON | 43.25±0.63a | 62.00±0.41a | 315.00±12.48a | 245.75±15.20a | 219.25±3.57a |
| NCC-L | 35.75±1.38b | 55.75±0.25b | 242.75±15.77b | 173.50±16.54b | 206.75±7.10b |
| NCC-H | 34.75±0.63bc | 53.75±0.25b | 162.25±11.48c | 100.00±2.16c | 148.25±14.56c |
| ENCC-L | 32.00±2.86bc | 54.75±1.03b | 225.25±15.52b | 90.00±4.92c | 187.25±8.92b |
| ENCC-H | 25.50±2.25c | 48.50±1.26c | 115.50±6.08d | 83.75±1.11c | 126.50±8.65d |
Group names refer to those described in Table 1.
Different letters (a–d) in a column indicate a statistically significant difference among groups (P <0.05).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; TCHO, total cholesterol; TG, triglyceride.
Fig. 3Effect of oral administration of normal and encapsulated curcumin on levels of (A) malondialdehyde (MDA) and (B) glutathione peroxidase (GSH-px) in liver tissue. Liver tissue was homogenized with Tris-HCl buffer, and MDA and GSH-px in the homogenates were analyzed. Group names refer to Table 1.